The Postoperative S Wave in Lead V5 and/or V6 Predicts Better Clinical Outcomes in Heart Failure Patients With Left
Kailun Zhu1, Chen He1, Haojie Zhu1
1Cardiac Arrhythmia Center, Fuwai Hospital, National Center for Cardiovascular Diseases, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing, China.
Background:
S wave in lead V5/6 has been reported as a marker indicated for successful left bundle branch (LBB) capture. This study aimed to evaluate the value of the S wave in lead V5/6 in predicting the long-term clinical outcomes in heart failure (HF) patients treated with left bundle area pacing (LBBAP).
Methods:
Consecutive HF patients receiving LBBAP were prospectively enrolled and followed at least 2 years. ECG were analyzed to identify the S wave in lead V5/6. The composite end point was all-cause mortality, HF hospitalization, and malignant ventricular arrhythmias. Non-response to LBBAP delivered cardiac resynchronization therapy (CRT) was defined as left ventricular ejection fraction improvement <5% at 6 months after implantation.
Results:
A total of 57 patients were included with the mean age of 59.90 ± 12.57 years and 39 (68.42%) males. S wave in V5/6 was observed in 38 patients. During a mean follow up of 29.84 ± 12.51 months, Kaplan-Meier curves showed a 77.8% reduction in risk of composite end point for V5/6 with S (HR 0.222; 95% CI 0.065, 0.756; log-rank, p = 0.0069). Multivariate Cox regression analysis revealed that V5/6 with S was associated with a lower risk of the composite end point by 69.0% (adjusted HR 0.31; 95% CI 0.09, 1.05; p = 0.041). The non-response rate of LBBAP was 22.58% in V5/6 with S and 58.82% in V5/6 without S (p = 0.012).
Conclusion:
S wave in lead V5 and/or V6 after LBBAP predicts better clinical outcomes, and has a better response rate of LBBAP for CRT in HF patients.
Related Concept Videos
Heart Failure II: Pathophysiology
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Inotropic Agents
Heart Failure III: Clinical Manifestations


